Prescription and Utilization of Low Molecular Weight Heparin in Usual Medical Practice for the Curative Treatment of Venous Thromboembolism in Patients With Cancer

Venous Thromboembolism Clinical Trial

Official title:

Prescription and Utilization of Low Molecular Weight Heparin in Usual Medical Practice for the Curative Treatment of Venous Thromboembolism in Patients With Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01803022
• Other study ID #: Tropique
• Status: Completed
• Phase: N/A
• First received: February 26, 2013
• Last updated: February 1, 2018
• Start date: November 2012
• Est. completion date: July 2013

Study information

• Verified date: February 2018
• Source: LEO Pharma
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The study purpose is to document the prescription and the use of Low Molecular Weight Heparin in usual medical practice in patients with cancer and established Venous Thromboembolism. This study also aims at gathering epidemiological data on the Low Molecular Weight Heparin therapy of Venous Thromboembolism in patients with cancer.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 419
• Est. completion date: July 2013
• Est. primary completion date: July 2013
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Subjects must provide informed consent

• Men or women aged 18 years or more

• Ongoing cancer disease recent diagnosis of veinous thromboembolism treatment with Low Molecular Weight Heparin before entry into the study

Exclusion Criteria:

• Contraindication to the use of Low Molecular Weight Heparin

Related Conditions & MeSH terms

• Thromboembolism
• Venous Thromboembolism

Locations

Country	Name	City	State
France	Hopital Saint Louis	Paris

Sponsors (1)

Lead Sponsor	Collaborator
LEO Pharma

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Prescription conditions and use of Low Molecular Weight Heparin in the French usual practice for the treatment of symptomatic Venous Thromboembolism in patients with cancer at up to 6 months		up to 6 months
Secondary	To evaluate the consistency of the Low Molecular Weight Heparin use with French national recommendations on the treatment of Venous Thromboembolism in patients with cancer.		up to 6 months
Secondary	To evaluate Venous Thromboembolism recurrences, bleeding, thrombocytopenia and deaths during Low Molecular Weight Heparin treatment		up to 6 months
Secondary	To describe clinical factors associated with treatment duration with Low Molecular Weight Heparin and those associated with the occurrence of Venous Thromboembolism in patients with cancer		up to 6 months
Secondary	To evaluate the anticoagulant treatment perception and satisfaction by patients with cancer disease with a validated questionnaire		up to 6 months

External Links

•   Result publication